VirX™, which is also branded as enovid™ in certain countries, is approved as a medical device in Israel, Bahrain, Thailand and Indonesia. It is also registered as a Class I medical device in Singapore, Nepal and the European Union where it received a CE mark.
It is not yet approved for sale in Canada or the United States.
VirXTM and enovidTM are identical formulations based on our NORSTM (Nitric Oxide Releasing Solution) platform technology. They have the same active ingredients and mechanisms of action as those nasal therapeutics used in our clinical trials.
For more information on VirXTM and enovidTM please visit this page.